Veru to Present Three Presentations at the 2022 American Society for Clinical Oncology Annual Meeting on June 3-7
31. Mai 2022 08:30 ET
|
Veru Inc.
MIAMI, May 31, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the...
Veru to Participate in Fireside Chat at the Jefferies Healthcare Conference on June 8, 2022
25. Mai 2022 08:30 ET
|
Veru Inc.
MIAMI, May 25, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the...
Veru Announces Appointment of Joel Batten to Lead U.S. Infectious Disease Franchise to Focus on Hospitalized COVID-19 Patients
18. Mai 2022 08:30 ET
|
Veru Inc.
MIAMI, May 18, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the...
Veru to Present at the H.C. Wainwright Global Investment Conference on May 24th 2022
17. Mai 2022 08:30 ET
|
Veru Inc.
MIAMI, May 17, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the...
Veru Reports Second Quarter Fiscal 2022 Results and Progress of Sabizabulin for COVID-19 Toward a Request for Emergency Use Authorization
12. Mai 2022 06:30 ET
|
Veru Inc.
--FDA States that Veru Should Submit Request for Emergency Use Authorization (EUA) Application Based on Positive Efficacy and Safety Data from the Phase 3 Clinical Study of Sabizabulin in Hospitalized...
FDA States that Veru Should Submit Request for Emergency Use Authorization (EUA) Based on Positive Efficacy and Safety Data from the Phase 3 Clinical Study of Sabizabulin in Hospitalized COVID-19 Patients
11. Mai 2022 06:30 ET
|
Veru Inc.
-- FDA Agrees that No Additional Efficacy Studies or Safety Data are Required to Support a Request for EUA -- -- A Request for EUA is Planned for Submission in Calendar 2Q 2022----Company Plans to...
FDA Has Granted Veru a Pre-Emergency Use Authorization (EUA) Meeting Date for Positive Sabizabulin Phase 3 COVID-19 Study
02. Mai 2022 08:30 ET
|
Veru Inc.
MIAMI, May 02, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company, today announced that the FDA has granted the Company a pre-Emergency Use Authorization (EUA) meeting on...
Veru to Report Fiscal 2022 Second-Quarter Financial Results, Host Conference Call on May 12th
28. April 2022 08:30 ET
|
Veru Inc.
MIAMI, April 28, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company, today announced that it will report financial results for its fiscal 2022 second quarter, on...
Veru Announces Oral Late-Breaking Presentation of Phase 2 Data of Sabizabulin for the Treatment of Hospitalized Severe COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome at the 32nd European Congress of Clinical Microbiology & Infectious Diseases
25. April 2022 08:30 ET
|
Veru Inc.
MIAMI, April 25, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company, today announced that results from the randomized placebo-controlled Phase 2 study of daily, oral...
Veru’s Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase 3 Study; Independent Data Monitoring Committee Halts Study Early for Overwhelming Efficacy
11. April 2022 06:30 ET
|
Veru Inc.
-- Independent Data Monitoring Committee Unanimously Recommends that Phase 3 Clinical Trial for Sabizabulin for Treatment of Hospitalized COVID-19 Patients at High Risk for ARDS Be Stopped Early Due...